Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2025-12-26 @ 12:44 AM
Study NCT ID:
NCT00206960
Status:
COMPLETED
Last Update Posted:
2011-09-19
First Post:
2005-09-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}, {'id': 'D003072', 'term': 'Cognition Disorders'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003006', 'term': 'Clopenthixol'}, {'id': 'D018967', 'term': 'Risperidone'}], 'ancestors': [{'id': 'D013892', 'term': 'Thioxanthenes'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D014966', 'term': 'Xanthenes'}, {'id': 'D006575', 'term': 'Heterocyclic Compounds, 3-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 56}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '1998-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-09', 'completionDateStruct': {'date': '2010-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2011-09-16', 'studyFirstSubmitDate': '2005-09-10', 'studyFirstSubmitQcDate': '2005-09-13', 'lastUpdatePostDateStruct': {'date': '2011-09-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-09-21', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'All examinations are done at baseline (patients and controls). In the patient group, they are repeated after 3 months of treatment', 'timeFrame': 'prospective'}, {'measure': 'PANSS', 'timeFrame': 'prospective'}, {'measure': 'SANS', 'timeFrame': 'prospective'}, {'measure': 'SAPS', 'timeFrame': 'prospective'}, {'measure': 'MRI', 'timeFrame': 'prospective'}, {'measure': 'fMRI', 'timeFrame': 'prospective'}, {'measure': 'startle response', 'timeFrame': 'prospective'}, {'measure': 'PrePulse Inhibition of the startle response (PPI)', 'timeFrame': 'prospective'}, {'measure': 'Cognition', 'timeFrame': 'prospective'}], 'secondaryOutcomes': [{'measure': 'The cognitive test battery comprised tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) as well as paper-and-pencil cognitive tests.', 'timeFrame': 'prospective'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['drug-naive', 'epidepride', 'single tomography', 'D2 receptor', 'information processing', 'PPI', 'antipsychotic treatment', 'MRI', 'fMRI', 'cognitive disturbances'], 'conditions': ['Schizophrenia']}, 'referencesModule': {'references': [{'pmid': '12399139', 'type': 'RESULT', 'citation': 'Mackeprang T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry. 2002 Nov 1;52(9):863-73. doi: 10.1016/s0006-3223(02)01409-9.'}, {'pmid': '15115949', 'type': 'RESULT', 'citation': 'Fagerlund B, Mackeprang T, Gade A, Glenthoj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr. 2004 May;9(5):364-74. doi: 10.1017/s1092852900009354.'}]}, 'descriptionModule': {'briefSummary': 'We wanted to compare dopamine D2 receptor activity, brain structure, brain function, sensory gating and cognition in neuroleptic-naive schizophrenic patients and matched healthy controls. Additionally, we wanted to examine the effects of 3 months of treatment with either low doses of a typical or an atypical antipsychotic compound on the same functions. The hypotheses were that schizophrenic patients suffered from disturbances in brain function and structure, information processing, and extrastriatal D2 receptor activity, and that these disturbances would be related to each other and to psychopathology. Additionally, we expected the atypical compound to have an effect on some of the disturbances in information processing, and that the atypical compound - in contrast to the typical drug - would show extrastriatal over striatal selectivity.', 'detailedDescription': '31 neuroleptic-naive schizophrenic patients and 25 matched controls were recruited from the greater Copenhagen area. The patients were randomized to treatment with either low doses of the typical antipsychotic compound, zuclopenthixol, or the atypical drug, risperidone. Patients and controls were examined at base-line and patients were re-examined after 3 months of treatment.The study has resulted in two finish Ph.D. theses (Torben Mackeprang and Birgitte Fagerlund).\n\nThe data has in part been published in:\n\nMackeprang T, Tjelle Kristiansen K, Glenthoj B. Prepulse inhibition of the startle response in drug-naïve, first-episode schizophrenic patients before and after 3 months of treatment with a typical or an atypical antipsychotic drug. Biological Psychiatry 2002; 52(9): 863-873.\n\nand\n\nFagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthoj BY. Effects of Low-Dose Risperidone and Low-Dose Zuclopenthixol on Cognitive Functions in First-Episode Drug-Naïve Schizophrenic Patients. CNS Spectr. 2004; 9: 364-74.\n\nand\n\nGlenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg L, Friberg L, Baaré W, Hemmingsen R, Videbæk C. Frontal dopamine D2/3 receptor binding in drug-naïve first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biological Psychiatry 2006; in press. Mar 30; \\[Epub ahead of print\\]. PMID: 16784819 \\[PubMed - as supplied by publisher\\].\n\nWe are at present conducting a five-year follow-up study of the same cohort of patients and controls and plan a ten-year follow-up as well. The follow-up studies focus on brain structure (MRI), brain function, information processing, and psychopathology. We will correlate changes in structure and function to treatment, but no interventions (pharmacological or otherwise) are planned.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* For patients: Clinical diagnosis of schizophrenia.\n* The controls were matched to the patients.\n\nExclusion Criteria:\n\n* Patients: Previous antipsychotic treatment, patients who were compulsorily hospitalised or deemed in acute need of medication, mental retardation\n* Controls: psychiatric diagnosis, psychiatric diagnosis in first-degree relatives, drug abuse, mental retardation'}, 'identificationModule': {'nctId': 'NCT00206960', 'briefTitle': 'Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia', 'organization': {'class': 'OTHER', 'fullName': 'University of Copenhagen'}, 'officialTitle': 'Effects of Classical and Atypical Antipsychotics on Dopamine Receptor Binding of 123I-epidepride, Cognition, Startle Response and Extrapyramidal Side-effects in Drug-naive First-episode Schizophrenic Patients', 'orgStudyIdInfo': {'id': '363002'}, 'secondaryIdInfos': [{'id': 'KF 01-078/97'}, {'id': 'KF 01-012/98'}, {'id': 'KF 11-057/99'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': '1', 'interventionNames': ['Drug: zuclopenthixol']}, {'type': 'ACTIVE_COMPARATOR', 'label': '2', 'interventionNames': ['Drug: risperidone']}], 'interventions': [{'name': 'zuclopenthixol', 'type': 'DRUG', 'otherNames': ['Cisordinol'], 'description': 'Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms', 'armGroupLabels': ['1']}, {'name': 'risperidone', 'type': 'DRUG', 'otherNames': ['Risperdal'], 'description': 'Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms', 'armGroupLabels': ['2']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'DK-2100', 'city': 'Copenhagen', 'country': 'Denmark', 'facility': 'Neurobiology Research Unit, University of Copenhagen, Rigshospitalet', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': 'DK-2400', 'city': 'Copenhagen NV', 'country': 'Denmark', 'facility': 'Dept. of Nuclear Medicine, University of Copenhagen, Bispebjerg Hospital'}, {'zip': 'DK-2400', 'city': 'Copenhagen NV', 'country': 'Denmark', 'facility': 'University of Copenhagen, Dept. F, Bispebjerg Hospital'}, {'zip': 'DK-2400', 'city': 'Copenhagen NV', 'country': 'Denmark', 'facility': 'University of Copenhagen, Dept. of Psychiatry E, Bispebjerg Hospital'}, {'zip': 'DK-2600', 'city': 'Glostrup Municipality', 'country': 'Denmark', 'facility': 'Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup', 'geoPoint': {'lat': 55.6666, 'lon': 12.40377}}, {'zip': 'DK-2650', 'city': 'Hvidovre', 'country': 'Denmark', 'facility': 'Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital', 'geoPoint': {'lat': 55.64297, 'lon': 12.47708}}], 'overallOfficials': [{'name': 'Birte Glenthoj, MD, DMSc', 'role': 'STUDY_DIRECTOR', 'affiliation': 'University of Copenhagen, Psychiatric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Birte Glenthoj', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Copenhagen', 'class': 'OTHER'}, {'name': 'Glostrup University Hospital, Copenhagen', 'class': 'OTHER'}, {'name': 'Rigshospitalet, Denmark', 'class': 'OTHER'}, {'name': 'Hvidovre University Hospital', 'class': 'OTHER'}, {'name': 'The Danish Medical Research Council', 'class': 'OTHER'}, {'name': 'Copenhagen Hospital Corporation', 'class': 'OTHER'}, {'name': 'Janssen-Cilag Ltd.', 'class': 'INDUSTRY'}, {'name': 'The Novo Nordic Foundation', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Professor of Psychopharmacology and Neuropsychiatry, Danish Center for Neuropsychiatric Schizophrenia Research', 'investigatorFullName': 'Birte Glenthoj', 'investigatorAffiliation': 'University of Copenhagen'}}}}